 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| 12345678910111213...2223» |
- | Halaven (eribulin mesylate) / Eisai
Retrospective data, Journal: Development and internal validation of a predictive model of overall and progression-free survival in eribulin-treated patients with breast cancer based on baseline peripheral blood parameters. (Pubmed Central) - Apr 12, 2025
Nomograms incorporating peripheral blood parameters may improve the accuracy of predicting OS and PFS in patients treated with eribulin. Our prediction model may help decision-making for breast cancer patients who are considering eribulin treatment.
- | Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
Journal: Profiling the gut and oral microbiota of hormone receptor-positive, HER2-negative metastatic breast cancer patients receiving pembrolizumab and eribulin. (Pubmed Central) - Apr 10, 2025
P2
Notably, B. fragilis NCTC 9343 supernatant induced dose-dependent lactate dehydrogenase (LDH) release from the MCF-7 (HR-positive/HER2-negative) BC cell line. These findings suggest that specific gut and oral microbiota may modulate the effectiveness of combinatory anti-BC therapies, potentially through the action of microbial metabolites.
- ||| P3 data, Journal, Head-to-Head: Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial. (Pubmed Central) - Apr 7, 2025
P3
These findings suggest that specific gut and oral microbiota may modulate the effectiveness of combinatory anti-BC therapies, potentially through the action of microbial metabolites. The results suggested that eribulin + HP is an option for first-line treatment of locally advanced/metastatic HER2+ BC.
- Halaven (eribulin mesylate) / Eisai
Efficacy and safety of eribulin in liposarcoma and leiomyosarcoma: A systematic review and meta-analysis (Villa Ciani) - Apr 3, 2025 - Abstract #SarcomaRC2025SARCOMA_RC_257;
Legal entity responsible for the study The authors. Funding Has not received any funding.
- Yondelis (trabectedin) / PharmaMar, J&J, Halaven (eribulin mesylate) / Eisai
Eribulin (E) versus trabectedin (T) therapy in patients with advanced liposarcoma: Efficacy comparison using real-world data evidence from TriNetX platform (Hall A) - Apr 3, 2025 - Abstract #SarcomaRC2025SARCOMA_RC_43;
Legal entity responsible for the study J. Rodriguez Pascual. Funding Has not received any funding.
- | Halaven (eribulin mesylate) / Eisai, Aliqopa (copanlisib) / Bayer
Trial completion, Enrollment change: Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer (clinicaltrials.gov) - Apr 3, 2025
P1/2, N=28, Completed, Sponsor: National Cancer Institute (NCI)
Funding Has not received any funding. Active, not recruiting --> Completed | N=106 --> 28
- | AiTan (rivoceranib) / HLB Bio Group, Halaven (eribulin mesylate) / Eisai, AiRuiKa (camrelizumab) / HLB Bio Group
New trial: Clinical Study on the Efficacy of Immunotherapy Combined with Targeted Therapy and Chemotherapy Versus Investigator's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer (EUDRACT) - Apr 2, 2025
P=N/A, N=246, Not yet recruiting, Sponsor: Sun Yat-sen Memorial Hospital Sun Yat-sen University; Sun Yat-sen Memorial Hospital Sun Yat-sen University
- | pazopanib / Generic mfg., Halaven (eribulin mesylate) / Eisai
Journal: Case Report: an extremely rare case of giant dedifferentiated retroperitoneal liposarcoma. (Pubmed Central) - Apr 1, 2025
Ongoing clinical trials suggest a shift towards multimodal therapy. This case report reports the largest retroperitoneal liposarcoma and underscores the complexity of managing retroperitoneal DDL.
- Halaven (eribulin mesylate) / Eisai
Long-term outcomes of eribulin?based neoadjuvant chemotherapy for triple?negative breast cancer: results of the randomized JBCRG-22 study (Hall B0) - Mar 29, 2025 - Abstract #ESMOBC2025ESMO_BC_504;
- || Avastin (bevacizumab) / Roche, Halaven (eribulin mesylate) / Eisai
Clinical data, Retrospective data, Journal: Treatment patterns and clinical outcomes in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer treated with chemotherapy: a large-scale data analysis using the Japanese claims database. (Pubmed Central) - Mar 28, 2025
Notably, the TTNTD shortens with successive treatments, and medical costs increase, intensifying the financial burden on patients. These findings indicate unmet needs for improved treatment options that enhance outcomes and reduce patient burden in advanced therapy lines.
- | Halaven (eribulin mesylate) / Eisai
Journal: Assessment of the Mechanisms of Action of Eribulin in Patients with Advanced Liposarcoma Through the Evaluation of Radiological, Functional, and Tissue Responses: A Prospective Monocentric Study (Malibu Study). (Pubmed Central) - Mar 28, 2025
Eribulin appears to exhibit non-mitotic activity involving both vascularization and cell differentiation in LPS patients. Further studies are needed to better define these effects.
- | Halaven (eribulin mesylate) / Eisai, vinorelbine tartrate / Generic mfg., paclitaxel / Generic mfg.
Journal: Selective tubulin-binding drugs induce pericyte phenotype switching and anti-cancer immunity. (Pubmed Central) - Mar 27, 2025
Moreover, a contractile pericyte signature was associated with overall better survival outcome in two independent breast cancer cohorts. This underscores the potential of re-purposing specific anti-cancer drugs to enable synergistic complementation with emerging immunotherapies.
- | AiTan (rivoceranib) / HLB Bio Group, Halaven (eribulin mesylate) / Eisai, AiRuiKa (camrelizumab) / HLB Bio Group
New P3 trial: Phase III Trial of Camrelizumab+Apatinib+Eribulin Vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer (clinicaltrials.gov) - Mar 21, 2025
P3, N=246, Not yet recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- || Review, Journal: New treatment options for generalized HER2-positive breast cancer in higher-line systemic palliative therapy. (Pubmed Central) - Mar 16, 2025
This underscores the potential of re-purposing specific anti-cancer drugs to enable synergistic complementation with emerging immunotherapies. In this case report, we describe the case of a highly pretreated patient with HER-2 positive metastatic breast cancer.
- |||| Melblez Kit (melphalan hepatic delivery system) / Delcath
New P2 trial: Evaluation of the Safety and Efficacy of Treatment W/High Dose Melphalan Given Directly Into the Liver Followed by Treatment W/approved Cancer Treatment or Approved Cancer Treatment Alone in Patients W/ Metastatic Breast Cancer W/liver Dominant Disease (clinicaltrials.gov) - Mar 13, 2025
P2, N=90, Not yet recruiting, Sponsor: Delcath Systems Inc.
- |||| Bria-IMT (SV-BR-1-GM) / BriaCell
Trial completion date, Trial primary completion date: BRIA-ABC: Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. (clinicaltrials.gov) - Mar 13, 2025
P3, N=404, Recruiting, Sponsor: BriaCell Therapeutics Corporation
In this case report, we describe the case of a highly pretreated patient with HER-2 positive metastatic breast cancer. Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Jan 2026
- || Preclinical, Review, Journal: Selinexor in the treatment of liposarcoma: from preclinical evidence to clinical practice. (Pubmed Central) - Mar 9, 2025
P1, P1/2,
Ongoing studies, such as the SeliSarc trial (NCT04595994) evaluating selinexor in combination with gemcitabine and the NRSTS2021 trial (NCT06239272) evaluating selinexor in paediatric soft tissue sarcoma, aim to further define its role. The results of these studies will be critical in determining whether selinexor can be incorporated into standard sarcoma treatment.
- | Halaven (eribulin mesylate) / Eisai
Journal, PARP Biomarker: Eribulin exerts multitarget antineoplastic activity in glioma cells. (Pubmed Central) - Mar 9, 2025
Eribulin demonstrates potent anti-glioma effects through apoptosis, mitochondrial dysfunction, and cell cycle disruption. These findings support its potential as a therapeutic option for glioblastoma treatment, warranting further investigation into its mechanisms and clinical applicability.
- | Halaven (eribulin mesylate) / Eisai
New P3 trial: Efficacy and Safety of Biweekly Regimen of Eribulin Versus a Standard Regimen for the Treatment of Locally Recurrent or Metastatic HER2-negative Breast Cancer: a Multicenter, Randomized, Open-label, Phase III Trial (clinicaltrials.gov) - Mar 4, 2025
P3, N=192, Enrolling by invitation, Sponsor: Ma Fei?MD
- | Datroway (datopotamab deruxtecan) / Daiichi Sankyo, AstraZeneca
Journal: Datopotamab deruxtecan (Datroway) for advanced breast cancer. (Pubmed Central) - Feb 27, 2025
These findings support its potential as a therapeutic option for glioblastoma treatment, warranting further investigation into its mechanisms and clinical applicability. No abstract available
- | Halaven (eribulin mesylate) / Eisai, tolinapant (ASTX660) / Otsuka
Enrollment open: Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer (clinicaltrials.gov) - Feb 26, 2025
P1, N=42, Recruiting, Sponsor: National Cancer Institute (NCI)
No abstract available Suspended --> Recruiting
- | Halaven (eribulin mesylate) / Eisai, paclitaxel / Generic mfg.
Journal: Small Molecules Identified by an In Silico Docking Screen Targeting Anaphase-Promoting Complex/Cyclosome Subunit 1 (APC1) Potentiate Paclitaxel-Induced Breast Cancer Cell Death. (Pubmed Central) - Feb 26, 2025
Two of the five compounds, which share a common 2-(trifluoromethyl)quinazolin-4-amine chemical structure, induced elevated levels of cell death in combination with paclitaxel, as observed by fluorescence-activated cell sorting (FACS). These two compounds will now serve as a starting point for further optimization and target validation experiments and for additional in silico screens in search of other chemically related small molecules that display more potent but specific anti-cancer cell effects.
- Halaven (eribulin mesylate) / Eisai
Eribulin-induced Pneumotoxicity in a Patient With Metastatic Triple Negative Breast Cancer: A Case Report (TP19) - Feb 24, 2025 - Abstract #ATS2025ATS_1495;
- | Piqray (alpelisib) / Novartis, Herceptin (trastuzumab) / Roche
Trial completion date, Trial primary completion date: Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) (clinicaltrials.gov) - Feb 24, 2025
P3, N=27, Active, not recruiting, Sponsor: Spanish Breast Cancer Research Group
These two compounds will now serve as a starting point for further optimization and target validation experiments and for additional in silico screens in search of other chemically related small molecules that display more potent but specific anti-cancer cell effects. Trial completion date: Nov 2024 --> Jun 2025 | Trial primary completion date: Nov 2024 --> Jun 2025
- || Halaven (eribulin mesylate) / Eisai, irinotecan / Generic mfg.
PK/PD data, Journal, Monotherapy: Efficacy, safety, and pharmacokinetics of eribulin as monotherapy or in combination with irinotecan for patients with pediatric rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, or Ewing sarcoma. (Pubmed Central) - Feb 22, 2025
Trial completion date: Nov 2024 --> Jun 2025 | Trial primary completion date: Nov 2024 --> Jun 2025 Eribulin, as monotherapy or combination therapy, exhibited a safety profile consistent with that observed previously in adult populations; however, efficacy in both studies was not considered adequate to advance investigation in these disease areas.
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
Efficacy of sacituzumab govitecan in triple-negative breast cancer with leptomeningeal carcinomatosis (Poster 2 | Exhibition Room, No.3 Bldg. 1F, Kobe International Exhibition Hall) - Feb 22, 2025 - Abstract #JSMO2025JSMO_1801;
- Successfully treated non-islet cell tumor hypoglycemia caused by a malignant solitary fibrous tumor (Poster 1 | Convention Hall, No.2 Bldg. 1F, Kobe International Exhibition Hall) - Feb 22, 2025 - Abstract #JSMO2025JSMO_1613;
- Chemotherapy for retroperitoneal sarcoma: real world experience in a single institute (Poster 2 | Exhibition Room, No.3 Bldg. 1F, Kobe International Exhibition Hall) - Feb 22, 2025 - Abstract #JSMO2025JSMO_1528;
- The treatment experience of desmoplastic small round cell tumor (DSRCT) (Poster 2 | Exhibition Room, No.3 Bldg. 1F, Kobe International Exhibition Hall) - Feb 22, 2025 - Abstract #JSMO2025JSMO_1522;
- Treatment patterns and clinical outcomes in HR+/HER2- metastatic breast cancer: Japanese claims database study (Room 11 | 502, 5F, Kobe International Conference Center) - Feb 22, 2025 - Abstract #JSMO2025JSMO_1190;
- Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Quality-of-life outcomes in HER2+ metastatic breast cancer patients treated with eribulin, trastuzumab, and pertuzumab (Room 11 | 502, 5F, Kobe International Conference Center) - Feb 22, 2025 - Abstract #JSMO2025JSMO_645;
- | Journal, BRCA Biomarker, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: A Case of Advanced Breast Cancer with SP142/22C3 Double Positive and BRCA Mutation Positive (Pubmed Central) - Feb 14, 2025
Pembrolizumab+carboplatin+gemcitabine was started as second-line therapy, and the tumor achieved partial response(PR)but developed PD within 6 months. After that, she was administrated olaparib, but PD was observed, and after the therapy with PTX+bevacizumab, she is now treated with eribulin.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Halaven (eribulin mesylate) / Eisai
Journal: Eribulin-Induced Peripheral Neuropathy in Locally Advanced or Metastatic Breast Cancer: Final Analysis of the Prospective Cohort IRENE Study. (Pubmed Central) - Feb 13, 2025
TEAEs were consistent with the established eribulin safety profile, with no new safety signals. Eribulin treatment did not appear to affect QoL, as measured by EQ-5D-3L and EQ-VAS, or patient-reported neuropathy symptoms, as measured by the PNQ.
- | Halaven (eribulin mesylate) / Eisai, tolinapant (ASTX660) / Otsuka
Trial suspension: Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer (clinicaltrials.gov) - Feb 6, 2025
P1, N=42, Suspended, Sponsor: National Cancer Institute (NCI)
Eribulin treatment did not appear to affect QoL, as measured by EQ-5D-3L and EQ-VAS, or patient-reported neuropathy symptoms, as measured by the PNQ. Recruiting --> Suspended
- | Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
Trial primary completion date, IO biomarker: EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma (clinicaltrials.gov) - Feb 4, 2025
P2, N=30, Recruiting, Sponsor: Australia New Zealand Gynaecological Oncology Group
Recruiting --> Suspended Trial primary completion date: Dec 2024 --> Mar 2025
- || Halaven (eribulin mesylate) / Eisai, rebastinib (DCC-2036) / Ono Pharma
P1 data, PK/PD data, Journal, Metastases: Phase Ib clinical and pharmacodynamic study of the TIE2 kinase inhibitor rebastinib with paclitaxel or eribulin in HER2-negative metastatic breast cancer. (Pubmed Central) - Jan 17, 2025
Trial primary completion date: Dec 2024 --> Mar 2025 In patients with MBC, the recommended phase 2 dose of rebastinib associated with pharmacodynamic evidence of TIE2 inhibition is either 50 or 100 mg PO BID in combination with paclitaxel or eribulin.
- | Halaven (eribulin mesylate) / Eisai
Journal, Real-world evidence: Unravelling Eribulin's role in metastatic breast cancer: evaluating benefits for both triple negative and non-triple negative patients in real-world scenarios in resource-constrained settings. (Pubmed Central) - Jan 16, 2025
Eribulin is a viable and safe option for treating heavily pre-treated MBC in real-world settings. The study found comparable efficacy in both TNBC and non-TNBC patients.
- | Journal, Metastases: Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. (Pubmed Central) - Jan 15, 2025
Results support Dato-DXd as a novel treatment option for patients with inoperable/metastatic HR+/HER2? breast cancer who have received one to two previous lines of chemotherapy in this setting.
- | CPO301 / CSPC Pharma, SYH2051 / CSPC Pharma
New P1/2 trial, Monotherapy: Clinical Trial of SYS6010 (clinicaltrials.gov) - Jan 15, 2025
P1/2, N=410, Not yet recruiting, Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.
- || Trial completion date, IO biomarker: SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Jan 15, 2025
P2, N=1460, Active, not recruiting, Sponsor: UNICANCER
breast cancer who have received one to two previous lines of chemotherapy in this setting. Trial completion date: Dec 2024 --> Dec 2025
- || Clinical, Review, Journal, BRCA Biomarker, PARP Biomarker: Second-Line Treatment Options for Patients with Metastatic Triple-Negative Breast Cancer: A Review of the Clinical Evidence. (Pubmed Central) - Jan 14, 2025
Exploratory data for fam-trastuzumab-deruxtecan suggest a survival benefit in human epidermal growth factor receptor 2-low, hormone-receptor-negative patients, but further solid evidence is required. Other chemotherapies with lower European Society for Medical Oncology-Magnitude of Clinical Benefit Scale scores may continue to be useful in highly selected patients.
- ||| Retrospective data, Journal, Adverse events: Drug classes associated with the development of fulminant type 1 diabetes: a retrospective analysis using the FDA adverse event reporting system database. (Pubmed Central) - Jan 12, 2025
This study provides insights into drug-induced FT1DM using the FAERS database, identifying specific drugs associated with an increased risk. The findings underscore the importance of pharmacovigilance in identifying potential drug triggers for FT1DM and emphasize the need for close monitoring of glucose levels in patients treated with these medications.
- | Journal: Confirmatory diagnosis and successive chemotherapeutic treatments of metastatic skeletal EWSR1::NFATC2 sarcoma: A case report. (Pubmed Central) - Jan 12, 2025
It is likely that there are more patients with undiagnosed EWSR1::NFATC2 sarcoma. To make a definitive diagnosis, a thorough investigation should be performed.
- Halaven (eribulin mesylate) / Eisai
A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937 (Level 1, West Hall; Poster Bd #: J15) - Jan 7, 2025 - Abstract #ASCOGU2025ASCO_GU_631;
P3
Erdafitinib remains an option for pts with FGFR3 alterations...Funding: National Institutes of Health/National Cancer Institute grants U10CA180888, U10CA180819. Eribulin is provided by Eisai.
- The Efficacy And Safety Of Folate Receptor a-Targeted Antibody-Drug Conjugate Therapy In Patients With High-Grade Epithelial Ovarian, Primary Peritoneal, Or Fallopian Tube Cancers: A Systematic Review And Meta-Analysis (Exhibition hall) - Jan 4, 2025 - Abstract #ESGO2025ESGO_1661;
The protocol was registered with PROSPERO (CRD42023491151).Results Ten studies with a total of 940 patients (859 treated with mirvetuximab soravtansine-gynx (MIRV), 45 with farletuzumab ecteribulin (MORAb-202), and 36 with luveltamab tazevibulin (STRO-002)) were included in this meta-analysis. The incidence of grade ?3 adverse events was 27% (95% CI: 0.19
- | Halaven (eribulin mesylate) / Eisai, utidelone IV (UTD1) / Beijing Biostar Technologies
Journal, Real-world evidence, Real-world, Metastases: Real world analysis of the efficacy and safety of eribulin compared to utidelone in combination with capecitabine for the treatment of metastatic breast cancer. (Pubmed Central) - Dec 20, 2024
In conclusion, either utidelone/capecitabine or eribulin chemotherapy may result in a survival benefit with a tolerable adverse effect profile and favorable safety profile in patients with metastatic breast cancer. The first-line use of eribulin resulted in better PFS and ORR than posterior-line use, and the combination of utidelone/capecitabine represents a more efficacious approach in the advanced first-line therapy of breast cancer.
- ||| izorlisib (MEN1611) / Menarini, Halaven (eribulin mesylate) / Eisai
Enrollment change, Monotherapy: SABINA: PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin (clinicaltrials.gov) - Dec 20, 2024
P2, N=14, Recruiting, Sponsor: MedSIR
The first-line use of eribulin resulted in better PFS and ORR than posterior-line use, and the combination of utidelone/capecitabine represents a more efficacious approach in the advanced first-line therapy of breast cancer. N=28 --> 14
- || Review, Journal, BRCA Biomarker, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: Targeted and cytotoxic inhibitors used in the treatment of breast cancer. (Pubmed Central) - Dec 18, 2024
Patients with ER-positive tumors are treated with 5-10 years of endocrine therapy and chemotherapy. For patients with metastatic breast cancer, standard first-line and follow-up therapy options include targeted approaches such as CDK4/6 inhibitors, PI3K inhibitors, PARP inhibitors, and anti-PDL1 immunotherapy, depending on the tumor type and molecular profile.
- | Halaven (eribulin mesylate) / Eisai, Aliqopa (copanlisib) / Bayer
Trial completion date, Trial primary completion date: Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer (clinicaltrials.gov) - Dec 18, 2024
P1/2, N=106, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
For patients with metastatic breast cancer, standard first-line and follow-up therapy options include targeted approaches such as CDK4/6 inhibitors, PI3K inhibitors, PARP inhibitors, and anti-PDL1 immunotherapy, depending on the tumor type and molecular profile. Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New trial, Real-world evidence: ALTER-BC-005: Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive?HR+? Metastatic Breast Cancer(MBC) . (clinicaltrials.gov) - Dec 16, 2024
P=N/A, N=80, Recruiting, Sponsor: Hunan Cancer Hospital